Knee Osteoarthritis (OA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Knee Osteoarthritis (OA) Market Outlook

Thelansis’s “Knee Osteoarthritis (OA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Knee Osteoarthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Knee Osteoarthritis (OA) Overview

Knee osteoarthritis (OA) is a common progressive joint disease that causes pain and disability. It is the most common form of OA, accounting for almost 4/5th of the global burden of the disease. Knee OA increases with age and obesity and is incurable except through knee arthroplasty, an effective treatment at an advanced stage of the disease but is responsible for substantial health costs. Knee osteoarthritis is characterized by chronic pain and functional disability. Pain results from inflammation and damage to the joint, including thickening of the joint capsule and the formation of osteophytes (bone spurs). A study found that 43.3% of people reported having pain, aching, or stiffness in a knee joint on most days. The prevalence of pain increased with age, from 34.2% in people aged 45 to 54 years to 56.6% in people aged 75 years and older. No drugs currently approved can prevent, stop, or even slow the progression of OA. The available medications that promise to mitigate the pain of OA have several risk/benefit considerations. For example, non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with a clinically relevant 50-100% increase in myocardial infarction or cardiovascular death risk.

• The global prevalence of knee OA was 16.0% in individuals aged 15 and over and 23.2% in individuals aged 40 and over. This means that one in six people over 15 worldwide has knee OA. The Knee osteoarthritis prevalence is higher in women than men and increases with age.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: